Barinthus Biotherapeutics (BRNS) Competitors $0.97 -0.41 (-29.71%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends BRNS vs. INBX, KYTX, AMRN, TIL, FULC, TSVT, OPT, MOLN, NBTX, and NKTXShould you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Inhibrx (INBX), Kyverna Therapeutics (KYTX), Amarin (AMRN), Instil Bio (TIL), Fulcrum Therapeutics (FULC), 2seventy bio (TSVT), Opthea (OPT), Molecular Partners (MOLN), Nanobiotix (NBTX), and Nkarta (NKTX). These companies are all part of the "pharmaceutical products" industry. Barinthus Biotherapeutics vs. Inhibrx Kyverna Therapeutics Amarin Instil Bio Fulcrum Therapeutics 2seventy bio Opthea Molecular Partners Nanobiotix Nkarta Barinthus Biotherapeutics (NASDAQ:BRNS) and Inhibrx (NASDAQ:INBX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, community ranking, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations. Do analysts rate BRNS or INBX? Barinthus Biotherapeutics currently has a consensus target price of $5.83, suggesting a potential upside of 501.25%. Inhibrx has a consensus target price of $27.00, suggesting a potential upside of 95.23%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Barinthus Biotherapeutics is more favorable than Inhibrx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Barinthus Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Inhibrx 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is BRNS or INBX more profitable? Inhibrx's return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Barinthus BiotherapeuticsN/A -34.26% -29.30% Inhibrx N/A N/A N/A Does the MarketBeat Community believe in BRNS or INBX? Inhibrx received 18 more outperform votes than Barinthus Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 59.62% of users gave Inhibrx an outperform vote. CompanyUnderperformOutperformBarinthus BiotherapeuticsOutperform Votes13100.00% Underperform VotesNo VotesInhibrxOutperform Votes3159.62% Underperform Votes2140.38% Does the media prefer BRNS or INBX? In the previous week, Barinthus Biotherapeutics had 7 more articles in the media than Inhibrx. MarketBeat recorded 13 mentions for Barinthus Biotherapeutics and 6 mentions for Inhibrx. Barinthus Biotherapeutics' average media sentiment score of 0.60 beat Inhibrx's score of 0.05 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Barinthus Biotherapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibrx 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, BRNS or INBX? Barinthus Biotherapeutics has higher earnings, but lower revenue than Inhibrx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBarinthus Biotherapeutics$800K47.95-$73.35M-$1.49-0.65Inhibrx$1.63M122.86-$154.96MN/AN/A Do insiders & institutionals have more ownership in BRNS or INBX? 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 82.5% of Inhibrx shares are held by institutional investors. 8.0% of Barinthus Biotherapeutics shares are held by company insiders. Comparatively, 22.2% of Inhibrx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryBarinthus Biotherapeutics and Inhibrx tied by winning 7 of the 14 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BRNS vs. The Competition Export to ExcelMetricBarinthus BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.36M$6.53B$5.15B$8.74BDividend YieldN/A8.16%5.18%4.08%P/E Ratio-0.654.9166.6713.57Price / Sales47.95376.691,276.8487.67Price / CashN/A51.2039.7035.24Price / Book0.249.686.475.93Net Income-$73.35M$154.43M$119.73M$225.73M7 Day Performance-28.13%-9.46%-5.13%-1.34%1 Month Performance-19.15%-7.27%-2.71%1.15%1 Year Performance-64.72%28.13%31.08%24.02% Barinthus Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BRNSBarinthus Biotherapeutics2.3244 of 5 stars$0.97-29.7%$5.83+501.3%-67.1%$38.36M$800,000.00-0.65107Short Interest ↑News CoverageGap DownHigh Trading VolumeINBXInhibrx3.9371 of 5 stars$14.99-3.0%N/A-34.2%$217.06M$1.63M0.00166Short Interest ↑News CoverageKYTXKyverna Therapeutics2.9003 of 5 stars$4.90-3.2%N/AN/A$211.44M$7.03M0.0096Analyst ForecastAnalyst RevisionNews CoverageAMRNAmarin0.386 of 5 stars$0.51-10.4%N/A-34.2%$209.48M$306.91M-5.67360Positive NewsTILInstil Bio2.8705 of 5 stars$32.20+2.1%N/A+294.1%$209.30MN/A-1.7549Analyst ForecastNews CoverageGap DownFULCFulcrum Therapeutics3.4297 of 5 stars$3.33-6.5%N/A-22.4%$207.80M$81.63M-9.51100Analyst ForecastAnalyst RevisionNews CoverageTSVT2seventy bio2.4942 of 5 stars$3.98-3.6%N/A+66.4%$204.97M$100.39M-2.14440News CoverageOPTOpthea2.3773 of 5 stars$3.42-8.6%N/A+72.3%$199.73M$120,000.000.008News CoverageGap UpHigh Trading VolumeMOLNMolecular Partners0.5565 of 5 stars$5.36-2.7%N/A+17.1%$196.66M$7.84M-2.49180Short Interest ↑NBTXNanobiotix2.3987 of 5 stars$4.14+5.9%N/A-34.5%$195.12M$39.18M0.00100News CoveragePositive NewsGap DownNKTXNkarta2.3687 of 5 stars$2.76-5.2%N/A+7.2%$194.77MN/A-1.47140 Related Companies and Tools Related Companies INBX Competitors KYTX Competitors AMRN Competitors TIL Competitors FULC Competitors TSVT Competitors OPT Competitors MOLN Competitors NBTX Competitors NKTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BRNS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BRNS Stock Alerts